Myopia Profile

Eyerising International

Eyerising International is an Australian MedTech company developing life-impacting eye-health therapy to slow the progression of myopia. 

Eyerising International sponsored articles.

Global insights on repeated low-level red light therapy: interview series A recent interview series with five experts from around the world sheds light on their experiences with RLRL. Read Full Article Repeated low-level red light therapy: a look at safety and efficacyRepeated low-level red light (RLRL) therapy is a new approach to myopia control: read about the research on safety and efficacy. Read Full Article Repeated low-level red light therapy in the clinic: Q&A with Song Chow, Jagrut Lallu and Simon RoseThree leading eyecare clinicians discuss using repeated low-level red light (RLRL) therapy in their practice. Read Full Article
Global insights on repeated low-level red light therapy: interview series A recent interview series with five experts from around the world sheds light on their experiences with RLRL. Read Full Article

Eyerising Myopia Management Device

The Eyerising myopia management device uses proprietary technology for administering Repeated Low-Level Red-Light (RLRL) therapy that enhances blood circulation in the ocular fundus, addressing sclera hypoxia and managing the axial elongation associated with myopia. It is backed by 2-year clinical trial results showing myopia control efficacy, and complies with Australian Standard IEC 60825-1:2014 for laser products safety. 

More about Eyerising Myopia Management Device

Eyerising International resources

eyerising-video.png

Eyerising Expert Video Interview Series Highlights

Eyerising International recently undertook a series of video interviews where global experts spoke to Dr Kate Gifford of Myopia Profile about their clinical experiences, observations and work with the Eyerising Myopia Management Device.